Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | IL1B | P01584 | 7/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.37 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31190600 | 1.00 | MAP2K4 (0.39) | MAP2K4STSIL1BP2RX7RORC | |
| SCHEMBL18837358 | 0.85 | MAP2K4 (0.40) | MAP2K4RORCALDH1A1KDM4EFAAH | |
| SCHEMBL5952500 | 0.85 | MAP2K4 (0.38) | MAP2K4STSIL1BP2RX7RORC | |
| SCHEMBL16724831 | 0.84 | MAP2K4 (0.39) | MAP2K4ALDH1A1KDM4EFAAHPOLB | |
| SCHEMBL5951848 | 0.84 | MAP2K4 (0.41) | MAP2K4RORCALDH1A1KDM4ELMNA | |
| SCHEMBL31190710 | 0.84 | MAP2K4 (0.41) | MAP2K4RORCALDH1A1KDM4ELMNA | |
| SCHEMBL29953968 | 0.82 | MAP2K4 (0.38) | MAP2K4RORCALDH1A1KDM4EFAAH | |
| SCHEMBL31190764 | 0.81 | MAP2K4 (0.39) | MAP2K4RORCALDH1A1KDM4EFAAH | |
| SCHEMBL4562257 | 0.80 | NOTUM (0.43) | RORCLMNATSHRPOLB | |
| SCHEMBL31190618 | 0.80 | MET (0.38) | MAP2K4ALDH1A1KDM4ELMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYSOWAY THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-11370770-B2 | 3-arylindazoles as selective MEK4 inhibitors | NORTHWESTERN UNIVERSITY (US) | 2022-06-28 | — | — | US | disclosed |
| US-11370770-B2 | 3-arylindazoles as selective MEK4 inhibitors | NORTHWESTERN UNIVERSITY (US) | 2022-06-28 | — | — | US | disclosed |
| US-20200399241-A1 | 3-ARYLINDAZOLES AS SELECTIVE MEK4 INHIBITORS | NORTHWESTERN UNIVERSITY (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200399241-A1 | 3-ARYLINDAZOLES AS SELECTIVE MEK4 INHIBITORS | NORTHWESTERN UNIVERSITY (US) | 2020-12-24 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | MAP2K4 252/4885STS 870/4885IL1B 3829/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | MAP2K4 376/4885STS 932/4885IL1B 2925/4885 |
| US-20200399241-A1 | 3-ARYLINDAZOLES AS SELECTIVE MEK4 INHIBITORS | MAP4K3, MAPK4, MAP3K4 | MAP2K4 39/4885STS 3737/4885IL1B 4622/4885 |
| US-11370770-B2 | 3-arylindazoles as selective MEK4 inhibitors | MAP4K3, MAPK4, MAP3K4 | MAP2K4 39/4885STS 3737/4885IL1B 4622/4885 |
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | STOML2, ATP2A3, ATP2A1 | MAP2K4 4180/4885STS 491/4885IL1B 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.